Benefits
Lung function improvement (FEV1 up to 16%)
In a 6-week randomized controlled trial in healthy subjects with self-reported pollution sensitivity, AlvioLife at 200 mg/day improved forced expiratory volume in 1 second (FEV1) by up to 16% vs placebo. FEV1 is the standard measure of airway obstruction used by pulmonologists and is the primary clinical outcome for respiratory interventions.
Lung capacity expansion (FVC up to 30%)
Same trial documented forced vital capacity (FVC) improvements of up to 30% — measuring total lung capacity available for breathing. FVC improvement is particularly relevant for athletes, those exposed to air pollution, and adults with mildly compromised respiratory function. Effect size meaningful in real-world breathing comfort and exercise tolerance.
Aerobic exercise capacity (6-min walk +7%)
AlvioLife improved 6-minute walk test performance by up to 7% in the healthy subjects trial — translating lung function improvements into real-world physical performance. The 6-min walk test is a validated submaximal exercise capacity measure used in pulmonology research. Effect supports the broader sports nutrition and active lifestyle applications beyond pure respiratory health.
Asthma symptom improvement (foundational evidence)
An earlier 56-day double-blind trial in 36 subjects with bronchial asthma found AlvioLife significantly improved emotional function (p=0.0305) and asthma symptom scores (p=0.0002) — with effects appearing as early as 14 days. Established the foundational efficacy base for AlvioLife in compromised respiratory populations. Published in Phytotherapy Research.
Immune biomarker modulation (IFN-γ up, IL-4 down)
56-day supplementation in the asthma trial significantly increased serum IFN-γ (p=0.0014) and reduced IL-4 (p=0.0497) vs placebo. The Th1/Th2 cytokine balance shift is mechanistically relevant to respiratory allergic conditions. Healthy subjects trial also documented positive changes in CD4+ T helper cells and reduced IL-8 inflammatory biomarker — confirming immune modulation extends to non-diseased populations.
Upper respiratory symptom reduction (WURSS-21 up to ~40%)
AlvioLife reduced upper respiratory tract symptoms by up to ~40% as measured by the Wisconsin Upper Respiratory Symptom Scale-21 (WURSS-21) — a validated patient-reported outcome for cold/flu symptoms. The effect supports broader cold/flu season immune support applications beyond pollution exposure or asthma indications.
Psychological well-being improvement (PGWBI up to 18%)
Psychological General Well-Being Index (PGWBI) scores improved by up to 18% in the AlvioLife group. Respiratory health affects emotional and psychological state — easier breathing translates to better mood and quality of life. 'Improved sense of well-being and healthy psychological wellness' is one of the more consumer-relevant outcomes for everyday users.
5-LOX inhibition mechanism (synergistic)
The Boswellia + Aegle marmelos combination has stronger 5-lipoxygenase (5-LOX) inhibition activity than either constituent alone — true synergistic effect. 5-LOX produces leukotrienes that drive airway inflammation. Inhibiting 5-LOX is the mechanism of pharmaceutical asthma drugs like montelukast and zileuton. AlvioLife provides natural 5-LOX inhibition supporting the respiratory effects.
Mechanism of action
5-Lipoxygenase (5-LOX) inhibition
AKBA from Boswellia serrata is one of the most well-characterized natural 5-LOX inhibitors. 5-LOX produces leukotrienes (LTB4, LTC4) that drive airway inflammation, bronchoconstriction, and mucus production. Inhibiting this pathway has the same mechanism as pharmaceutical asthma drugs like montelukast (Singulair®) and zileuton.
Synergistic Boswellia + Aegle activity
The combination of Boswellia serrata and Aegle marmelos shows stronger 5-LOX inhibition than either constituent alone — a true synergistic effect rather than additive. The mechanism explains why AlvioLife achieves robust clinical effects at the relatively low 200 mg/day dose. Patented composition protects this specific synergy.
Th1/Th2 cytokine balance shift
AlvioLife increases IFN-γ (a Th1 cytokine) and reduces IL-4 (a Th2 cytokine), shifting immune balance away from the allergic Th2-skewed pattern associated with asthma and allergic respiratory conditions. The shift reduces airway hyperresponsiveness and may underlie the asthma symptom improvements documented in the pivotal trial.
CD4+ T helper cell modulation
Healthy subjects trial documented positive changes in CD4+ T helper cell percentages — supporting immune function alongside respiratory benefits. The mechanism connects respiratory and immune health, explaining AlvioLife's positioning in immune formulations beyond pure respiratory applications.
IL-8 inflammation reduction
AlvioLife reduced IL-8 (interleukin-8) inflammatory biomarker in the healthy subjects trial. IL-8 is a chemokine recruiting neutrophils to sites of inflammation — particularly relevant in airway inflammation from pollution and infection. Reducing IL-8 limits neutrophil-driven tissue damage in the lungs.
Clinical trials
2021 6-week randomized controlled trial of AlvioLife at 200 mg/day vs placebo in healthy subjects with self-reported air pollution sensitivity. Three-arm design also included 200 mg AlvioLife + 200 mg licorice extract combination. Outcomes: lung function (FEV1), lung capacity (FVC), 6-minute walk test, WURSS-21 symptoms, PGWBI well-being, CD4+, IL-8 biomarkers.
Healthy subjects with self-reported sensitivity to air pollution. 6-week intervention.
AlvioLife improved FEV1 by up to 16%, FVC by up to 30%, 6-minute walk performance by up to 7%, and WURSS-21 upper respiratory symptoms by up to ~40%. PGWBI psychological well-being scores improved by up to 18%. Perceived immune status improved as early as 3 weeks. Positive changes in CD4+ T helper cells and reduced IL-8 inflammatory biomarker. Safe and well-tolerated. Basis for Health Canada respiratory health claim approval.
Double-blind placebo-controlled trial of AlvioLife at 200 mg/day for 56 days in subjects with bronchial asthma. Published in Phytotherapy Research 2018;32(1):140-150 (doi: 10.1002/ptr.5963). Authors: Yugandhar P, Rao KM, Sengupta K. Foundational evidence demonstrating respiratory and inflammatory biomarker effects.
36 subjects with bronchial asthma. 56-day intervention.
Emotional function (p=0.0305) and asthma symptom scores (p=0.0002) improved as early as 14 days vs placebo. 56-day supplementation significantly increased serum IFN-γ (p=0.0014) and reduced IL-4 (p=0.0497). The Th1/Th2 cytokine balance shift is mechanistically relevant to allergic respiratory conditions. Established AlvioLife's mechanism foundation that the subsequent healthy subjects trial extended to non-diseased populations.
Beyond AlvioLife-specific trials, AKBA-standardized Boswellia extracts have extensive class evidence for 5-lipoxygenase (5-LOX) inhibition and inflammatory disease applications. Boswellia has been used in Ayurvedic medicine for thousands of years, with modern research characterizing AKBA as the most potent 5-LOX-inhibiting boswellic acid.
Various — adults across multiple Boswellia trials in inflammatory conditions.
AKBA-rich Boswellia extracts consistently inhibit 5-LOX activity in vitro and in vivo, with anti-inflammatory effects extending to joint, respiratory, gut, and other inflammatory conditions. AlvioLife's 30% AKBA standardization places it among the higher-AKBA Boswellia products in the market. The Aegle marmelos addition provides synergistic 5-LOX inhibition beyond Boswellia alone.